Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate

Eur Urol. 2009 Nov;56(5):874-7; quiz 876. doi: 10.1016/j.eururo.2009.01.019. Epub 2009 Jan 20.

Abstract

We present the case of an 81-yr-old man with a prostatic adenocarcinoma and a metastatic carcinoid. Simultaneous occurrence of hormonally treated adenocarcinoma of the prostate and a carcinoid has been described before. The pathogenesis of this coincidence is largely unclear; however, androgen deprivation therapy might play a key role in neuroendocrine differentiation of adenocarcinoma cells. Early recognition of the carcinoid syndrome is crucial, as surgical cure is not possible after metastasis. We provide a brief review of recent literature.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / pathology
  • Aged, 80 and over
  • Androgen Antagonists / therapeutic use*
  • Anilides / therapeutic use*
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Biopsy
  • Carcinoid Tumor / drug therapy
  • Carcinoid Tumor / pathology*
  • Carcinoid Tumor / secondary
  • Humans
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / pathology*
  • Male
  • Malignant Carcinoid Syndrome / drug therapy
  • Neoplasms, Multiple Primary*
  • Nitriles / therapeutic use*
  • Positron-Emission Tomography
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Somatostatin / analogs & derivatives
  • Somatostatin / therapeutic use
  • Tosyl Compounds / therapeutic use*

Substances

  • Androgen Antagonists
  • Anilides
  • Antineoplastic Agents, Hormonal
  • Nitriles
  • Tosyl Compounds
  • Somatostatin
  • bicalutamide